|
Patent landscape, scope, and claims: |
US Patent 5,413,999: Scope, Claims Structure, and US Patent Landscape for HIV Protease Inhibitor Chemistry
US Patent 5,413,999 is a composition-of-matter and use patent directed to a family of defined substituted compounds (formula-based) with broad substituent latitude, and to pharmaceutical compositions and methods for HIV/AIDS indications. The dependent claim chain narrows key variables (notably V absent) and constrains substituent classes through successively tighter definitions. Claim 9 and the method claims align to AIDS, HIV infection, and HIV protease inhibition.
1. What is the claim scope at a structural level?
Independent claim coverage (Claim 1)
Claim 1 covers:
- A compound of a formula (structure defined by variables including V, Q, R1, R3, R5, R12, and salts).
- Two high-level structural branches for variable V/Q:
- V is absent or a defined alternative substituent pattern.
- Q is absent or oxygen/nitrogen/heterocycle options (with heterocycle substitution latitude).
The scope is driven by three main variable “engines”:
- R1 substitution (alkyl/aryl/cycloalkyl/heterocycle with extensive permissible substituents).
- R5 substitution (functionalized amino-alkyl-heterocycle / amino-alkyl moieties, plus a set of specifically listed heteroaromatic and fused-ring substituents).
- R3 / R12 substitution and salt forms, including protected amine options such as Boc and carbamate/amide-like substituent constructs expressed in the claim language.
Claim 1 also explicitly includes pharmaceutically acceptable salts.
Dependent claims tighten the template
- Claim 2: further restricts the formula by stating V is absent and fixes certain variables (leaving R1 and R3 substitution options still broad but reduced).
- Claim 3: adds further narrowing while retaining the same overall family concept (again V absent).
- Claim 4: makes the heterocycle at a key position specifically enumerated to a defined list of heterocycles (piperidinyl, pyridyl, thienyl, pyrrolyl, thiazolyl, imidazolyl, furyl, benzimidazolyl, pyrazinyl, isoxazolyl, pyridazinyl, quinolinyl) with substitution latitude.
- Claim 5: limits R1 to C1-4 alkyl substituted with pyridyl or aryl, and R3 to narrower benzyl-functional substitution options.
- Claim 6: identifies a discrete selection for R1 from a defined list (again expressed structurally in the claim text via “selected from ##STR316##”).
- Claim 7: adds another compound/formula branch (independent at the claim-set level, but still within the patent’s family).
- Claims 8–13: compositions and therapeutic methods for HIV/AIDS and HIV protease inhibition.
2. How do the key claim variables expand or restrict coverage?
V and Q
- V: Claim 1 allows V absent or present (with a defined alternative). Claims 2–5 and later narrowing state V is absent.
- Q: Claim 1 includes Q absent or oxygen/nitrogen/heterocycle options. This supports a broader “core scaffolding” in Claim 1 than in later dependent claims that explicitly collapse V.
Practical effect: Claim 1 captures multiple core variants; dependent claims focus on a subset defined by V absent, narrowing infringement risk for competitors using the “V present” variants.
R1 (broad substitution backbone)
Claim 1’s R1 is expressed as either:
-
1) C1-4 alkyl unsubstituted or substituted with one or more of:
- halo
- C1-3 alkoxy
- aryl (unsubstituted or substituted with C1-4 alkyl, amino, hydroxy, or aryl)
- W-aryl or W-benzyl where W = O, S, NH
- 5–7 member cycloalkyl optionally substituted with halo, C1-3 alkoxy, or aryl
- heterocycle optionally substituted with oxo, halo, C1-4 alkoxy, C1-4 alkyl
- and protected/functional side-chain motifs, including:
- Boc
- NH–SO2 C1-3 alkyl
- NR2
- COOR
- ((CH2)m O)n R with m 2–5 and n 0–3
-
2) aryl (unsubstituted or substituted with halo, hydroxy, NO2 or NR2, C1-4 alkyl, C1-3 alkoxy)
- with additional explicitly written substitution patterns
-
3) additional heterocycle / carbocycle options including Boc and other carbocyclic substituent patterns.
-
4) heterocycle optionally substituted with oxo, halo, amino, C1-4 alkoxy, C1-4 alkyl.
-
5) carbocyclic optionally substituted with halo, amino, C1-4 alkoxy.
-
Claim 4 restricts the heterocycle list to specific named rings (piperidinyl etc.).
-
Claim 5 further restricts R1 to C1-4 alkyl substituted with pyridyl or aryl.
-
Claim 6 narrows R1 to a structurally defined selected set.
Practical effect: Claim 1 has a very wide R1 envelope; the infringement-relevant narrowing steps occur in Claim 4 (heterocycle list) and Claim 5–6 (specific R1 pattern/selection).
R5 (functionalized amino-alkyl and ring substituent space)
Claim 1 defines R5 through three buckets:
- W-(CH2)m-NR6R7, where:
- W is O, S, or NH.
- m = 2, 3, 4, or 5
- R6 and R7 independently are hydrogen or C1-6 alkyl, and the alkyl can bear C1-3 alkoxy or NR2 substituents.
- A “joined-together” 5–7 member heterocycle (example given: morpholino-like) with up to two additional heteroatoms.
- (CH2)q-NR6R7, where q = 1–5, with restrictions that R6/R7 are not both simple H/unsubstituted alkyl per claim text.
- Specific aromatic/heteroaromatic substituent options, including:
- benzofuryl
- indolyl
- azacycloalkyl
- azabicyclo C7–11 cycloalkyl
- benzopiperidinyl
- with substitution by C1-4 alkyl and/or the claim’s embedded substitution rules.
Practical effect: R5 is broader in Claim 1 than in dependent forms that do not re-enlarge the bucket; if a competitor uses R5 outside these categories, Claim 1 coverage is weakened.
R3 and R12; salt coverage
- R3 in dependent claims is consistently described as benzyl optionally substituted with:
- hydroxy
- C1-3 alkoxy bearing additional OH
- a structural fragment expressed in the claim text as ##STR306 / ##STR309 / ##STR312 / ##STR314 depending on the dependent claim.
- R12 is “##STR302## or pharmaceutically acceptable salt thereof” in the claim text supplied, indicating salt forms are expressly within scope.
3. What are the therapeutic and composition claims?
Composition claim
- Claim 8: A pharmaceutical composition comprising a compound according to claims 3, 4, 5, or 6 and a pharmaceutically acceptable carrier.
Scope note: Composition coverage is tied to specific compound claims, not directly to claim 1. This makes dependent chemical narrowing relevant for enforceability.
Indication / method claims
- Claim 9: composition “for use” in:
- treatment of AIDS
- treatment of HIV infection
- inhibition of HIV protease
- Claim 10: another composition claim directed to a specific compound drawn as ##STR318## with carrier.
- Claims 11–13: methods of treating or inhibiting via administering an effective amount of a compound according to claims 5 or 7:
- Claim 11: treating AIDS
- Claim 12: treating HIV infection
- Claim 13: inhibiting HIV protease
Practical effect: The method claims narrow enforceable chemical sets to claim 5 or claim 7 in the supplied text, which matters for any competitor’s design-around at the R1/R3/R5 pattern level.
4. How does the claim chain narrow from broad template to enforceable subsets?
Narrowing map across claims 1–6
Below is the narrowing logic that controls claim-to-claim enforceability:
| Claim |
Core restriction stated in text |
Additional narrowing on substituents |
| 1 |
V absent or (V present variant) |
R1 broad; R5 broad (W-(CH2)m-NR6R7 and listed aromatic heterocycles); Q options included |
| 2 |
V is absent |
R1 and R3 remain broadly defined but aligned to the claim 2 template |
| 3 |
V is absent |
R1 and R3 options narrowed compared to claim 2 (less permissive lists in the supplied text) |
| 4 |
V absent |
R1 heterocycle explicitly enumerated (piperidinyl, pyridyl, thienyl, etc. plus substitution latitude); R3 fixed to benzyl options as described |
| 5 |
V absent |
R1 limited to C1-4 alkyl substituted with pyridyl or aryl; R3 benzyl options constrained further |
| 6 |
(template present) |
R1 limited to structurally selected set “selected from ##STR316##” |
Enforcement posture by claim type
- Composition & method claims hinge on claims 3–6 (Claim 8) and claims 5 or 7 (Claims 11–13). That makes Claim 5 a central infringement checkpoint.
- Claim 1 has broad chemical coverage, but it is not directly the composition/method chemical anchor in the supplied text.
5. Patent landscape for US “5,413,999” HIV protease inhibitor claims (scope-relevant positioning)
This patent’s claim language places it in the late-1990s era of HIV protease inhibitor chemistry where many patent families used:
- formula-based general structures,
- extensive substituent permutations,
- and method-of-treatment claims tied to AIDS/HIV protease.
Landscape drivers affecting freedom-to-operate
For a competitor, the relevant landscape questions are not “does a compound have the same general scaffolding,” but:
- Does the competitor’s compound fall inside the R1 enumerations (especially Claim 4 list) and the tighter Claim 5 pattern (C1-4 alkyl substituted with pyridyl or aryl)?
- Does the competitor’s R5 match the functionalized amino-alkyl architectures and the listed aromatic/heteroaromatic options in Claim 1?
- Does the competitor avoid V-absent template coverage, if their compound uses the “V present” variant admitted in Claim 1 but not in claims 2–5?
In practice, design-around typically targets one of those definitional pinch points while staying within potency and pharmacokinetic constraints.
Where the claim text signals enforcement priority
- Claim 5 and Claim 7 feed directly into the method claims (11–13).
- Claim 8 limits compositions to compounds in claims 3–6.
- Claim 4’s enumerated heterocycle list is a classic infringement bottleneck because it forces a direct comparison against competitor R1 heterocycle identity.
6. Business implications: how to use this claim scope for R&D screening
Compound evaluation checklist based on claim language
For any candidate protease inhibitor analog screened against this patent:
- Core variables
- confirm whether the competitor has the V absent configuration that matches claims 2–5 (for method/composition anchoring).
- R1
- map R1 to one of the claim 5 allowable categories:
- C1-4 alkyl with pyridyl or aryl substitution
- check Claim 4 heterocycle match if the candidate uses heterocycles beyond pure aryl:
- piperidinyl, pyridyl, thienyl, pyrrolyl, thiazolyl, imidazolyl, furyl, benzimidazolyl, pyrazinyl, isoxazolyl, pyridazinyl, quinolinyl
- R3
- verify benzyl substitution pattern is within the claim’s allowed benzyl substituents (hydroxy and/or C1-3 alkoxy bearing additional OH and the specific protected/functional fragment referenced by ##STR).
- R5
- validate the R5 moiety matches one of:
- W-(CH2)m-NR6R7 with m 2–5 and W in {O,S,NH}
- (CH2)q-NR6R7 with q in 1–5 and the restriction that R6/R7 not fall into the prohibited simplest combinations
- listed aromatic/heteroaromatic rings (benzofuryl/indolyl/azacycloalkyl/azabicyclo C7–11/benzopiperidinyl) substituted with C1-4 alkyl as permitted.
Strategic point
A screening tool should score candidates against each claim “gate” separately:
- V-gate
- R1-gate (Claim 4 list and Claim 5 pattern)
- R3-gate
- R5-gate
Then compute a “coverage probability” based on which exact gates align.
Key Takeaways
- Claim 1 is the broadest chemical scaffold coverage; it admits multiple configurations for V and Q, with expansive substituent options for R1 and R5.
- Claims 2–5 enforce a major narrowing by stating V is absent, and Claim 4 further narrows R1 heterocycles to a specific enumerated list.
- Claim 5 creates the most enforceable chemical pinch point for methods (Claims 11–13) by limiting R1 to C1-4 alkyl substituted with pyridyl or aryl and tightening R3 to defined benzyl substitution patterns.
- Composition coverage (Claim 8) ties to claims 3–6, while method-of-treatment coverage (Claims 11–13) ties to claims 5 or 7 in the claim text provided.
FAQs
1. Which claim is the primary chemical breadth entry point?
Claim 1.
2. Which claim explicitly requires “V is absent” and therefore is central to enforceable subsets?
Claims 2–5 (all state V is absent in the supplied claim text).
3. Where is the strongest R1 constraint located?
Claim 4 (heterocycle is limited to a defined list) and Claim 5 (R1 limited to C1-4 alkyl substituted with pyridyl or aryl).
4. Which claims support pharmaceutical compositions and what do they depend on?
Claim 8 (composition) depends on compounds in claims 3, 4, 5, or 6.
5. Which claims support method-of-treatment and HIV protease inhibition?
Claims 11–13, each administering effective amounts of compounds according to claims 5 or 7.
References
[1] United States Patent 5,413,999 (HIV/AIDS and HIV protease inhibition; formula-based substituted compounds; pharmaceutical compositions; method claims).
More… ↓
⤷ Start Trial
|
